Reader TTS

Access through your institution Buy or subscribe To the Editor: Manufacture of monoclonal antibodies (mAb) and related biologics is performed in eukaryotic cell lines to allow proper

glycosylation, which is often critical for function. The first mAbs were produced in the mouse-derived cell lines SP2/0 and NS0, which have the genetic makeup to produce proteins containing

nonhuman glycan structures, such as galactose-α-1,3-galactose (α-Gal) and _N_-glycolylneuramic acid1, that can adversely affect safety and half-life. The best example is Erbitux (cetuximab),

produced in SP2/0 cells, clinical use of which has been associated with α-Gal–specific, IgE-mediated anaphylactic responses2. In addition, patients with IgE antibodies to α-Gal may

experience allergic reactions to red meat3,4. The quantity of α-Gal required to induce hypersensitivity reactions is not known; however, it is clear that binding of IgE antibodies against

α-Gal is an important trigger in this pathology2. This is a preview of subscription content, access via your institution RELEVANT ARTICLES Open Access articles citing this article. *

EVALUATING CLINICAL IMPACT OF A SHORTENED INFUSION DURATION FOR RAMUCIRUMAB: A MODEL-BASED APPROACH * Ling Gao * , Yiu-Keung Lau *  … Paolo Abada _Cancer Chemotherapy and Pharmacology_ Open

Access 02 February 2021 * CMAB009 PLUS IRINOTECAN VERSUS IRINOTECAN‐ONLY AS SECOND‐LINE TREATMENT AFTER FLUOROPYRIMIDINE AND OXALIPLATIN FAILURE IN KRAS WILD‐TYPE METASTATIC COLORECTAL

CANCER PATIENTS: PROMISING FINDINGS FROM A PROSPECTIVE, OPEN‐LABEL, RANDOMIZED, PHASE III TRIAL * Yuankai Shi * , Jin Li *  … Xuenong Ouyang _Cancer Communications_ Open Access 24 May 2019 *

ROLE AND MECHANISM OF GALACTOSE-ALPHA-1,3-GALACTOSE IN THE ELICITATION OF DELAYED ANAPHYLACTIC REACTIONS TO RED MEAT * Christiane Hilger * , Jörg Fischer *  … Tilo Biedermann _Current

Allergy and Asthma Reports_ Open Access 23 January 2019 ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year

only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during

checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Qian, J. et al. _Anal. Biochem._ 364, 8–18

(2007). Article  CAS  PubMed  Google Scholar  * Chung, C.H. et al. _N. Engl. J. Med._ 358, 1109–1117 (2008). Article  CAS  PubMed  PubMed Central  Google Scholar  * Jacquenet, S.,

Moneret-Vautrin, D.A. & Bihain, B.E. _J. Allergy Clin. Immunol._ 124, 603–605 (2009). Article  CAS  PubMed  Google Scholar  * Commins, S.P. et al. _J. Allergy Clin. Immunol._ 123,

426–433 (2009). Article  CAS  PubMed  Google Scholar  * Ashford, D.A. et al. _J. Biol. Chem._ 268, 3260–3267 (1993). CAS  PubMed  Google Scholar  * Bosques, C.J. et al. _Nat. Biotechnol._

28, 1153–1156 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  * Vultaggio, A. et al. _Allergy_ 65, 657–661 (2010). Article  CAS  PubMed  Google Scholar  * Jefferis, R.

_Biotechnol. Prog._ 21, 11–16 (2005). Article  CAS  PubMed  Google Scholar  * Smith, D.F. et al. _J. Biol. Chem._ 265, 6225–6234 (1990). CAS  PubMed  Google Scholar  * Jones, A.J. et al.

_Glycobiology_ 17, 529–540 (2007). Article  CAS  PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS We thank M. Geukes, A.H. Simmelink and N.I.L. Derksen for valuable technical

assistance, and R. Taylor for his enthusiastic support. AUTHOR INFORMATION Author notes * Jeroen J Lammerts van Bueren and Theo Rispens: These authors contributed equally to this work.

AUTHORS AND AFFILIATIONS * Genmab, Utrecht, The Netherlands Jeroen J Lammerts van Bueren, Sandra Verploegen, Patrick H C van Berkel, Jan G J van de Winkel & Paul W H I Parren * Sanquin

Research, Amsterdam, The Netherlands Theo Rispens, Tjitske van der Palen-Merkus & Steven Stapel * Asthma and Allergic Diseases Center, University of Virginia, Charlottesville, Virginia,

USA Lisa J Workman, Hayley James & Thomas A E Platts-Mills * Department of Immunology, Immunotherapy Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands Jan G J van

de Winkel Authors * Jeroen J Lammerts van Bueren View author publications You can also search for this author inPubMed Google Scholar * Theo Rispens View author publications You can also

search for this author inPubMed Google Scholar * Sandra Verploegen View author publications You can also search for this author inPubMed Google Scholar * Tjitske van der Palen-Merkus View

author publications You can also search for this author inPubMed Google Scholar * Steven Stapel View author publications You can also search for this author inPubMed Google Scholar * Lisa J

Workman View author publications You can also search for this author inPubMed Google Scholar * Hayley James View author publications You can also search for this author inPubMed Google

Scholar * Patrick H C van Berkel View author publications You can also search for this author inPubMed Google Scholar * Jan G J van de Winkel View author publications You can also search for

this author inPubMed Google Scholar * Thomas A E Platts-Mills View author publications You can also search for this author inPubMed Google Scholar * Paul W H I Parren View author

publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Paul W H I Parren. ETHICS DECLARATIONS COMPETING INTERESTS J.J.L.v.B., S.V.,

P.H.C.v.B, J.G.J.v.d.W. and P.W.H.I.P. are Genmab employees and Genmab warrants and/or stock. T.R. has received research support rhgouh his institution from Genmab. SUPPLEMENTARY INFORMATION

SUPPLEMENTARY TEXT AND FIGURES Supplementary Figures 1–5, Supplementary Tables 1 and 2, and Supplementary Methods (PDF 1046 kb) RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS

ARTICLE CITE THIS ARTICLE van Bueren, J., Rispens, T., Verploegen, S. _et al._ Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact

therapeutic antibody Fc domains. _Nat Biotechnol_ 29, 574–576 (2011). https://doi.org/10.1038/nbt.1912 Download citation * Published: 11 July 2011 * Issue Date: July 2011 * DOI:

https://doi.org/10.1038/nbt.1912 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently

available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative